Mechanisms of Response to Diesel Exhaust in Subjects With Asthma
Visão geral do estudo
Status
Condições
Descrição detalhada
The investigators will also characterize selected polymorphisms in glutathione-S-transferase (GST) genes that have been implicated in susceptibility to air pollutants. Outcome measures will include lung function, bronchial responsiveness to bronchodilator, exhaled nitric oxide, induced sputum for inflammatory markers (IL6 and IL8), and exhaled breath condensate for nitrite, 8-isoprostane, 20-HETE (20-hydroxyeicosatetraenoic acid), nitrotyrosine and pH.
In this pilot project, parallel studies are being carried out in the human exposure chambers at two NIEHS centers, the EOHSI-CEED (Environmental and Occupational Health Sciences Institute- Center for Environmental Exposure and Disease) and the Penn-CEET (University of Pennsylvania-Center of Excellence in Environmental Toxicology). The joint project will enable each center to validate research results in a second population and include new biomarkers of pulmonary inflammation. Each center will recruit, consent, and collect data on its own subjects. Only de-identified data will be shared between the centers.
Tipo de estudo
Contactos e Locais
Locais de estudo
-
-
Pennsylvania
-
Philadephia, Pennsylvania, Estados Unidos, 19104
- Airways Biology Initiative at Penn Presbyterian Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Subject is an adult male or female between 18 and 55 years of age inclusive.
- Subject must have a prior history of a physician's diagnosis of asthma with reversible airway obstruction (shown by a greater than 12% increase in FEV1 following bronchodilator; or a positive methacholine challenge done following the screening visit. If methacholine challenge is required for qualification, a physician will be on-site for the test. Subject's asthma has been stable for the past six months with no change in asthma therapy.
- The subject has been a non-smoker for the past year and should have less than a 10-pack year history.
- Subject must be free of other significant pulmonary diseases (i.e., cystic fibrosis, tuberculosis, interstitial lung disease and bronchopulmonary dysplasia.
- The subject must be capable of and willing to provide written informed consent.
- The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.
The subject has no significant DE exposure that would include occupations such as truck driver, heavy equipment operator and railroad maintenance.
-
Exclusion Criteria:
- As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study.
- The subject has received an investigational drug or participated in any other research trial within 30 days or five half-lives or twice the duration of the biological effect of any drug (whichever is longer) prior to the current study.
- Oral steroids within the last 6 months.
- Less than 12% FEV1 response to bronchodilator or negative methacholine challenge.
- Hospital admission for asthma in past 6 months.
- The subject has a history of alcohol or drug abuse within the last 5 years.
- The subject has history of hepatitis B, hepatitis C or HIV virus.
- The subject has a history of cardiovascular disease including hypertension or says yes to one of the cardiovascular risk questions on the screening questionnaire.
- The subject has a history of diabetes.
- The subject is pregnant or lactating.
The subject has daily exposure to DE, i.e., trucking or heavy machine operators.
-
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
FEV1 response to bronchodilator, following DE compared with filtered air (primary outcome)
Prazo: Up to 3 weeks
|
Up to 3 weeks
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Exhaled nitric oxide
Prazo: Up to 3 weeks
|
Up to 3 weeks
|
|
8-isoprostane in exhaled breath condensate
Prazo: 1 year
|
1 year
|
|
Nitrite in exhaled breath condensate
Prazo: 1 year
|
1 year
|
|
pH in exhaled breath condensate
Prazo: 1 year
|
1 year
|
|
20-HETE(20-hydroxyeicosatetraenoic acid)levels in exhaled breath condensate
Prazo: 1 year
|
1 year
|
|
Cell differential in induced sputum
Prazo: 1 year
|
1 year
|
|
Glutathione-S-transferase (GST)polymorphisms
Prazo: Visit 1
|
Visit 1
|
|
Peak Flow
Prazo: Up to 3 weeks
|
Up to 3 weeks
|
|
Forced Vital Capacity (FVC)
Prazo: Up to 3 weeks
|
Up to 3 weeks
|
|
FEV1/FVC ratio
Prazo: Up to 3 weeks
|
Up to 3 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Reynold A Panettieri, Jr., MD, University of Pennsylvania
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 817330
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .